<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kataru RP</submitter><funding>Emerson Collective Cancer Research Fund</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><pagination>eabc0836</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8567054</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(695)</volume><pubmed_abstract>Exogenous administration of lymphangiogenic growth factors is widely used to study changes in lymphatic function in pathophysiology. However, this approach can result in off-target effects, thereby generating conflicting data. To circumvent this issue, we modulated intracellular VEGF-C signaling by conditionally knocking out the lipid phosphatase PTEN using the &lt;i>Vegfr3&lt;/i> promoter to drive the expression of &lt;i>Cre-lox&lt;/i> in lymphatic endothelial cells (LECs). PTEN is an intracellular brake that inhibits the downstream effects of the activation of VEGFR3 by VEGF-C. Activation of Cre-lox recombination in adult mice resulted in an expanded functional lymphatic network due to LEC proliferation that was independent of lymphangiogenic growth factor production. Furthermore, compared with lymp</pubmed_abstract><journal>Science signaling</journal><pubmed_title>Lymphatic-specific intracellular modulation of receptor tyrosine kinase signaling improves lymphatic growth and function.</pubmed_title><pmcid>PMC8567054</pmcid><funding_grant_id>T32 CA009501</funding_grant_id><funding_grant_id>HL111130</funding_grant_id><funding_grant_id>R01 HL111130</funding_grant_id><funding_grant_id>P30 CA008748</funding_grant_id><funding_grant_id>R01 AI079178</funding_grant_id><funding_grant_id>T32 AR071302</funding_grant_id><funding_grant_id>691032</funding_grant_id><pubmed_authors>Baik JE</pubmed_authors><pubmed_authors>Lu TT</pubmed_authors><pubmed_authors>Ortega S</pubmed_authors><pubmed_authors>Park HJ</pubmed_authors><pubmed_authors>Shin J</pubmed_authors><pubmed_authors>Ly CL</pubmed_authors><pubmed_authors>Mehrara BJ</pubmed_authors><pubmed_authors>Kataru RP</pubmed_authors><pubmed_authors>Schwartz N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lymphatic-specific intracellular modulation of receptor tyrosine kinase signaling improves lymphatic growth and function.</name><description>Exogenous administration of lymphangiogenic growth factors is widely used to study changes in lymphatic function in pathophysiology. However, this approach can result in off-target effects, thereby generating conflicting data. To circumvent this issue, we modulated intracellular VEGF-C signaling by conditionally knocking out the lipid phosphatase PTEN using the &lt;i>Vegfr3&lt;/i> promoter to drive the expression of &lt;i>Cre-lox&lt;/i> in lymphatic endothelial cells (LECs). PTEN is an intracellular brake that inhibits the downstream effects of the activation of VEGFR3 by VEGF-C. Activation of Cre-lox recombination in adult mice resulted in an expanded functional lymphatic network due to LEC proliferation that was independent of lymphangiogenic growth factor production. Furthermore, compared with lymp</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-22T22:04:07.405Z</modification><creation>2025-04-06T03:54:03.714Z</creation></dates><accession>S-EPMC8567054</accession><cross_references><pubmed>34376570</pubmed><doi>10.1126/scisignal.abc0836</doi></cross_references></HashMap>